Current Report Filing (8-k)
June 28 2018 - 4:07PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (date of earliest event reported): June 28, 2018
OWC
PHARMACEUTICAL RESEARCH CORP.
(Exact Name of Registrant as Specified in its Charter)
Commission
File No.: 0-54856
Delaware
|
|
98-0573566
|
(State
of Incorporation)
|
|
(I.R.S.
Employer Identification No.)
|
2
Ben Gurion Street, Ramat Gan, Israel
|
|
5257334
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
Telephone Number, including area code: +972-72-260-8004
Not
Applicable
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ]
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ]
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
8.01 Other Events.
OWC Pharmaceutical Research Corp. (“OWC”)
through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., announces the successful completion of the first part of
its Phase I, placebo controlled, maximal dose study (the “Psoriasis Study”) to determine the safety and tolerability
of topical ointment containing medical grade cannabis (the “Topical Ointment”) in healthy volunteers. The study is
being performed by Professor Aviv Barzilai, Director of the Department of Dermatology at Chaim Sheba Medical Center. Sheba is a
university-affiliated hospital that serves as Israel’s national medical center and is one of the leading integrated medical
centers in the Middle East. The completed part of the study consisted of application of escalating doses of the Topical Ointment
to healthy volunteers and was successfully completed with no adverse effects. After completion of the second part of this study,
the company plans to initiate a phase II clinical study to demonstrate the efficacy of Topical Ointment in treating mild to moderate
psoriasis and other inflammatory skin diseases.
Mr. Mordechai Bignitz, the Chief Executive
Officer of OWC commented, “We are very pleased to see the successful completion of this stage of the clinical testing program.
OWC is committed to the development and validation of cannabis-based products for the treatment of debilitating and life-threatening
diseases and is investing significant resources to prove that our products are both safe and efficacious. This study constitutes
an important step in bringing relief to millions of people that do not currently have effective therapies for diseases such as
psoriasis.”
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
OWC Pharmaceutical Research Corp.
|
|
|
|
|
By:
|
/s/
Mordechai Bignitz
|
|
Name:
|
Mordechai
Bignitz
|
|
Title:
|
Chief
Executive Officer
|
Date:
June 28, 2018
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Aug 2024 to Sep 2024
OWC Pharmaceuticals Rese... (CE) (USOTC:OWCP)
Historical Stock Chart
From Sep 2023 to Sep 2024